$VERV News
Last published 1y ago
- 1y agoLLYVERVLilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular riskPR NewswireEli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a ...
- 1y agoLLYVERVLilly and Verve announce expiration of Verve tender offerPR NewswireEli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (NASDAQ: VERV) today announced that the tender offer to purchase all of the issued and ...
- 1y agoLLYVERVLilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular riskPR NewswireEli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a Boston-based clinical-stage company developing genetic medicines for ...
- 1y agoVERVVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on May 30, 2025, the company granted
- 1y agoVERVVerve Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON , May 28, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that management will participate in
- 1y agoVERVVerve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial ResultsGlobeNewswireReported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 demonstrating dose-dependent decreases in blood LDL-C and PCSK9 Mean reduction in LDL-C of 53%, with a maximum reduction of 69%,
- 1y agoVERVVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON , May 02, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on April 30, 2025, the company granted
- 1y agoVERVVerve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9GlobeNewswireSingle infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort VERVE-102 was
- 1y agoVERVVerve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9GlobeNewswireBOSTON, April 11, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that the U.S. Food and Drug Administration
- 1y agoVERVVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, April 04, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on March 31, 2025, the company
- 1y agoABOSCLYMLENZSLDB+1Climb Bio Appoints Seasoned Biotech Leaders to Board of DirectorsGlobeNewswireWELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors.
- 1y agoVERVVerve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single DoseGlobeNewswireBOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced the clearance of its Investigational New
- 1y agoVERVVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on February 28, 2025, the company
- 1y agoVERVVerve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireInitial data from the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in the second quarter of 2025, with final dose escalation data in the second half of 2025 VERVE-102 has been
- 1y agoVERVVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on January 31, 2025, the company
- 1y agoVERVVerve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech ConferenceGlobeNewswireBOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and
- 1y agoVERVVerve Therapeutics Announces Pipeline Progress and Anticipated 2025 MilestonesGlobeNewswireInitial data for the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in second quarter of 2025 Dosing in the Heart-2 trial has moved to the 0.6 mg/kg cohort VERVE-301 nominated as development
- 1y agoVERVVerve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireBOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that Sekar Kathiresan, M.D., co-founder and
- 1y agoVERVVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on December 31, 2024, the company
- 1y agoVERVVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29, 2024, the company
- 2y agoVERVVerve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial ResultsGlobeNewswireSeven participants across two cohorts dosed in the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9; Initial data planned for the first half of 2025 First participant dosed in the Pulse-1 Phase 1b clinical
- 2y agoVERVVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON , Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024, the company
- 2y agoVERVVerve Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights - VERVPR NewswireThe Gross Law Firm issues the following notice to shareholders of Verve Therapeutics, Inc. (NASDAQ: VERV). Shareholders who purchased shares of VERV...
- 2y agoVERVVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on September 30, 2024, the company
- 2y agoVERVInvestors in Verve Therapeutics, Inc. Should Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights - VERVPR NewswireThe Gross Law Firm issues the following notice to shareholders of Verve Therapeutics, Inc. (NASDAQ: VERV). Shareholders who purchased shares of VERV...
- 2y agoVERVDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve TherapeuticsGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Verve To Contact Him Directly To Discuss Their Options If you suffered losses
- 2y agoVERVThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Verve Therapeutics Lawsuit - VERVPR NewswireThe Gross Law Firm issues the following notice to shareholders of Verve Therapeutics, Inc. (NASDAQ: VERV). Shareholders who purchased shares of VERV...
- 2y agoVERVThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Verve Therapeutics Lawsuit - VERVPR NewswireThe Gross Law Firm issues the following notice to shareholders of Verve Therapeutics, Inc. (NASDAQ: VERV). Shareholders who purchased shares of VERV...
- 2y agoVERVThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Verve Therapeutics, Inc. Lawsuit – VERVGlobeNewswireNEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Verve Therapeutics, Inc. (NASDAQ:VERV). Shareholders who purchased shares of VERV during the class period
- 2y agoVERVShareholders of Verve Therapeutics, Inc. Should Contact The Gross Law Firm Before October 28, 2024 to Discuss Your Rights - VERVPR NewswireThe Gross Law Firm issues the following notice to shareholders of Verve Therapeutics, Inc. (NASDAQ: VERV). Shareholders who purchased shares of VERV...
- 2y agoVERVVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on August 30, 2024, the company
- 2y agoVERVINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve TherapeuticsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Verve Therapeutics, Inc. ("Verve" or the...
- 2y agoVERVDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve TherapeuticsGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Verve To Contact Him Directly To Discuss Their Options If you suffered losses
- 2y agoVERVVerve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial ResultsGlobeNewswireHeart-2 clinical trial of VERVE-102 enrolling in the U.K. and Canada; Clinical Trial Application cleared in Australia Heart-2 and PCSK9 program data update planned for first half of 2025 Phase 1b clinical trial
- 2y agoVERVVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on July 31, 2024, the company granted
- 2y agoVERVVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, July 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today
- 2y agoVERVVerve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of DirectorsGlobeNewswireBOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today
- 2y agoVERVVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today
- 2y agoVERVVerve Therapeutics Announces Leadership UpdateGlobeNewswireTroy Lister, Ph.D., to be promoted to chief scientific officer Andrew Bellinger, M.D., Ph.D., will depart the Company and serve in an advisory capacity BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a
- 2y agoVERVVerve Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today
- 2y agoVERVVerve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial ResultsGlobeNewswireFirst patient dosed in Heart-2 Phase 1b clinical trial of VERVE-102 VERVE-201 clinical trial initiation on track for the second half of 2024 Received first milestone payment from Eli Lilly for collaboration on an in
- 2y agoVERVVerve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102GlobeNewswireVERVE-102 is an investigational in vivo base editing medicine designed to permanently inactivate the PCSK9 gene in the liver to durably reduce blood low-density lipoprotein cholesterol Heart-2 enrolling patients with
- 2y agoVERVVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today
- 2y agoVERVWolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Verve Therapeutics, Inc. for potential violations of federal securities lawsPR NewswireWolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is...
- 2y agoVERVVerve Therapeutics Announces Updates on its PCSK9 ProgramGlobeNewswireHeart-1 clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg of VERVE-101 Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT elevation and
- 2y agoVERVVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today
- 2y agoVERVVerve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today
- 2y agoVERVVerve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswireThree Clinical Stage Programs Targeting PCSK9 and ANGPTL3 Expected in 2024 Announced First Human Proof-of-Concept Data for In Vivo Base Editing from Ongoing Heart-1 Phase 1b Clinical Trial of VERVE-101 in November 2023
- 2y agoVERVVerve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceGlobeNewswireBOSTON, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today
- 2y agoVERVVerve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireBOSTON, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today